
|Articles|July 1, 2004
New Products & Services
Lexington, MA-Indevus Pharmaceuticals announced that trospium chloride (Sanctura) has been approved by the FDA for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5








